🟢 ProMIS Neurosciences is trading 6.86% up today after zero ARIA-E cases in interim PRECISE-AD data

ProMIS Neurosciences is trading 6.86% up at $13.39 after management highlighted encouraging blinded biomarker trends and a clean early safety profile for PMN310 at the September 9 Cantor Global Healthcare Conference.

• Interim PRECISE-AD data showed zero ARIA-E cases; full 12-month results are expected in the first quarter of 2027.
• The company said it remains funded through 2027, despite broader U.S. equity markets trading lower on September 9, 2026.